Compare Apple Inc (AAPL) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apple Inc vs Sana Biotechnology Inc — how do they compare? Apple Inc trades at $301.54 (market cap $4.45T), while Sana Biotechnology Inc trades at $3.87 (market cap $1.13B). The key difference: Apple Inc is far larger — about 3938.1× Sana Biotechnology Inc's market cap, and Apple Inc pays a 0.35% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| AAPL | SANA | |
|---|---|---|
Market Cap | $4.45T | $1.13B |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $340.08 | $5.92 |
52-Week Low | $224.90 | $2.68 |
Enterprise Value | $4.47T | $1.05B |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAPL trades at $301.42, down 2.22% on the day, with a bearish technical signal. The stock shows strong fundamentals, including a 26.91% net income margin and consistent earnings beats. Recent news highlights Apple's leadership in smartphone shipments and AI potential through its 2.5 billion active devices, though it faces challenges from union disputes and potential earnings pressure.
Outlook remains positive with a consensus price target of $337.63, implying 12% upside. Risks include weaker iPhone sales, regulatory scrutiny from EU fines, and competitive pressures. Analyst sentiment is bullish (63.64% buy ratings), but technical weakness and near-term headwinds warrant caution.
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
